先为达生物与辉瑞中国 达成商业化战略合作

Core Insights - The partnership between Xianweida Biotech and Pfizer China marks a significant milestone in the commercialization of Enogratide, the world's first approved cAMP biased GLP-1 receptor agonist, highlighting the recognition of Chinese innovative drugs by top international pharmaceutical companies [1][2] Group 1: Partnership Details - Xianweida Biotech and Pfizer China have entered into an exclusive commercialization agreement for Enogratide in mainland China, with Pfizer responsible for product promotion and market coverage [1] - Xianweida Biotech will receive up to $495 million in total payments, which includes upfront, registration, and sales milestone payments [1] Group 2: Product Efficacy - Enogratide has shown significant results in clinical trials, with over 80% of patients in the 1.2 mg dosage group achieving target blood sugar levels, and the efficacy sustained for up to 52 weeks [2] - The drug achieved an average weight reduction of 15.4% over 48 weeks, with 92.8% of participants experiencing a weight loss of over 5% [2] Group 3: Strategic Importance - The collaboration is part of Pfizer's long-term strategic plan in the metabolic field, addressing the growing demand from Chinese patients, particularly in light of the current adult obesity rate of 14.1% in China [3] - The partnership aligns with China's health initiatives, including the formal inclusion of "healthy weight management" in the Healthy China Action [3]